Hepatocellular carcinoma and other malignancies in autoimmune hepatitis

Digestive Diseases and Sciences

Volumn 58, Issue 6, 2013, Pages 1459-1476

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune hepatitis; Extrahepatic neoplasm; Hepatocellular cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; DNA; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MERCAPTOPURINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SORAFENIB; TRANSCRIPTION FACTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BUDD CHIARI SYNDROME; CANCER INCIDENCE; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIABETES MELLITUS; ECHOGRAPHY; FATTY LIVER; HEMOCHROMATOSIS; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MELANOMA; MORTALITY; MULTIPLE MYELOMA; NEOPLASM; NEW ZEALAND; NONHODGKIN LYMPHOMA; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; RISK FACTOR; SARCOMA; SKIN CANCER; STOMACH CANCER; SWEDEN; UTERINE CERVIX CANCER;

CARCINOMA, HEPATOCELLULAR; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; WORLD HEALTH;

EID: 84879500243     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2525-5     Document Type: Review

References (230)

1. Czaja AJ, Summerskill WH. Malignancy in chronic liver disease. Gastroenterology. 1977;73:192-193.
2. Jakobovits AW, Gibson PR, Dudley FJ. Primary liver cell carcinoma complicating autoimmune chronic active hepatitis. Dig Dis Sci. 1981;26:694-699.
3. Burroughs AK, Bassendine MF, Thomas HC, Sherlock S. Primary liver cell cancer in autoimmune chronic liver disease. Br Med J. 1981;282:273.
4. Bjarnason I, Magnusson B, Bjornsson S. Idiopathic chronic active hepatitis and hepatic cell carcinoma. Acta Med Scand. 1982;211:225.
5. Satake Y, Takada K, Ikeda K, et al. A case of primary liver cell cancer complicating lupoid hepatitis. Jpn J Med. 1988;27:83-86.
6. Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology. 1988;8:1679-1683.
7. Motoo Y, Wakatsuki T, Tanaka N, et al. Resected case of hepatocellular carcinoma associated with lupoid hepatitis. J Gastroenterol Hepatol. 1989;4:295-298.
8. Thung SN, Bach N, Fasy TM, Jordon D, Schaffner F. Hepatocellular carcinoma associated with autoimmune chronic active hepatitis. Mt Sinai J Med. 1990;57:165-168.
9. Yousuf M, Kiyosawa K, Sodeyama T, et al. Development of hepatocellular carcinoma in a man with auto-immune chronic active hepatitis. J Gastroenterol Hepatol. 1992;7:66-69.
10. Sakaguchi T, Nakamura S, Suzuki S, et al. Hepatocellular carcinoma associated with lupoid hepatitis: a review of Japanese reports. Surg Today. 1995;25:838-842.
11. Yamazaki K, Kamiyama T, Shiba S, et al. An aged male patient with autoimmune hepatitis complicated by hepatocellular carcinoma. Intern Med. 1999;38:422-425.
12. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1984;87:1222-1227.
13. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology. 2004;39:1631-1638.
14. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008;103:1944-1951.
15. Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology. 2008;48:863-870.
16. Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology. 1990;11:1044-1049.
17. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333:958-963.
18. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890-897.
19. Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int. 2005;25:734-739.
20. Ryder SD, Koskinas J, Rizzi PM, et al. Hepatocellular carcinoma complicating autoimmune hepatitis: role of hepatitis C virus. Hepatology. 1995;22:718-722.
21. Shi Y, Wu YH, Wu W, et al. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012;32:231-240.
22. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci. 2000;45:1944-1948.
23. Miyake Y, Iwasaki Y, Terada R, et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2006;24:1197-1205.
24. Hino-Arinaga T, Ide T, Kuromatsu R, et al. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol. 2012;47:569-576.
25. Hardee JT, Breth GF, El-Serag HB. Hepatocellular carcinoma associated with autoimmune hepatitis. J Clin Gastroenterol. 2003;37:271-272.
26. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576.
27. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342-348.
28. Kew MC, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis. 1984;4:136-146.
29. Benvegnu L, Noventa F, Bernardinello E, et al. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut. 2001;48:110-115.
30. Montalto G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:13-20.
31. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transpl Proc. 1969;1:106-112.
32. Penn I. Tumor incidence in human allograft recipients. Transpl Proc. 1979;11:1047-1051.
33. Penn I. Depressed immunity and the development of cancer. Clin Exp Immunol. 1981;46:459-474.
34. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985;78:44-49.
35. Wang KK, Czaja AJ, Beaver SJ, Go VL. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology. 1989;10:39-43.
36. Werner M, Almer S, Prytz H, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol. 2009;50:388-393.
37. Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology. 2012;55:522-529.
38. Riegler JL. Preneoplastic conditions of the liver. Semin Gastrointest Dis. 1996;7:74-87.
39. Ferenci P, Fried M, Labrecque D, et al. World Gastroenterology Organisation guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis. 2010;19:311-317.
40. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
41. Yang JD, Kim WR. Surveillance for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10:16-21.
42. Voiculescu M, Winkler RE, Moscovici M, Neuman MG. Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic. J Gastrointestin Liver Dis. 2008;17:315-322.
43. Mailey B, Buchberg B, Prendergast C, et al. A disease-based comparison of liver transplantation outcomes. Am Surg. 2009;75:901-908.
44. Teixeira AC, Mente ED, Castro-e-Silva O, et al. Treatment of hepatocellular carcinoma with liver transplantation: a single-center experience from Brazil. Transpl Proc. 2010;42:502-504.
45. Sohal DP, Sun W. Hepatocellular carcinoma: prevention and therapy. Curr Oncol Rep. 2011;13:186-194.
46. Song P, Tobe RG, Inagaki Y, et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32:1053-1063.
47. Gheorghe L, Iacob S, Bolog N, et al. Overlap syndrome between autoimmune hepatitis and primary biliary cirrhosis complicated by hepatocellular carcinoma. Rom J Gastroenterol. 2004;13:33-38.
48. Nishiyama R, Kanai T, Abe J, et al. Hepatocellular carcinoma associated with autoimmune hepatitis. J Hepatobiliary Pancreat Surg. 2004;11:215-219.
49. Okino H, Satoh T, Watanabe J, Masumoto A, Takeda S. Hepatocellular carcinoma arising from autoimmune hepatitis: report of a case. Surg Today. 2007;37:716-718.
50. Meza-Junco J, Montano-Loza AJ, Martinez-Benitez B, Kimura-Hayama E. Hepatocellular carcinoma in patients with autoimmune liver diseases: two case reports and literature review. Ann Hepatol. 2007;6:122-126.
51. Ward SC, Deniz K, Roayaie S, Qin L. Multifocal hepatocellular carcinoma and precancerous lesions in a patient with autoimmune hepatitis-related cirrhosis. Semin Liver Dis. 2008;28:123-127.
52. Teufel A, Weinmann A, Centner C, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol. 2009;15:578-582.
53. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci. 2011;56:578-585.
54. Yamamoto K, Hiura M, Tabaru A, et al. Rapid progression of hepatocellular carcinoma in a patient with autoimmune hepatitis. Intern Med. 2011;50:1409-1413.
55. Leung J, Dowling L, Obadan I, et al. Risk of non-melanoma skin cancer in autoimmune hepatitis. Dig Dis Sci. 2010;55:3218-3223.
56. Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci. 2010;55:2712-2726.
57. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology. 2010;139:58-72.
58. Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des. 2011;17:3120-3140.
59. Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-I. Inflamm Allergy Drug Targets. 2012;11:337-350.
60. Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part-II. Inflamm Allergy Drug Targets. 2012;11:351-363.
61. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110:848-857.
62. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981;2:1129-1133.
63. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-472.
64. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687-1695.
65. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131-136.
66. Sun CA, Wu DM, Lin CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol. 2003;157:674-682.
67. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148.
68. Darwish MA, Amer AF, El-Moeity AA, Darwish NM. Association of hepatitis C virus with liver cirrhosis and hepatocellular carcinoma compared with hepatitis B virus in Egyptian patients. J Egypt Public Health Assoc. 1997;72:569-589.
69. Chiesa R, Donato F, Tagger A, et al. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev. 2000;9:213-216.
70. Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2005;51:313-333.
71. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009;29:315-330.
72. Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol. 2009;15:2314-2328.
73. Czaja AJ. Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol. 2011;25:689-700.
74. Czaja AJ, dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci. 1998;43:2149-2155.
75. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:2051-2057.
76. Muratori P, Czaja AJ, Muratori L, et al. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol. 2005;11:1862-1866.
77. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379-388.
78. Migita K, Watanabe Y, Jiuchi Y, et al. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int. 2012;32:837-844.
79. Caballeria L, Pares A, Castells A, et al. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol. 2001;96:1160-1163.
80. Hsing AW, McLaughlin JK, Olsen JH, et al. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer. 1995;60:160-162.
81. Elmberg M, Hultcrantz R, Ekbom A, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology. 2003;125:1733-1741.
82. Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 2001;33:647-651.
83. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99-103.
84. Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol. 2008;43:1232-1240.
85. Poulsen LO, Thulstrup AM, Mellemkjaer L, Vilstrup H, Sorensen HT. Mortality and causes of death in patients with "lupoid hepatitis." A long-term follow-up study in Denmark. Dan Med Bull. 2002;49:263-265.
86. De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet. 1995;345:413-415.
87. Chagas AL, Kikuchi LO, Oliveira CP, et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res. 2009;42:958-962.
88. Czaja AJ. Drug choices in autoimmune hepatitis: part A - steroids. Expert Rev Gastroenterol Hepatol. 2012;6:603-615.
89. Czaja AJ. Drug choices in autoimmune hepatitis: part B - nonsteroids. Expert Rev Gastroenterol Hepatol. 2012;6:617-635.
90. Watanabe T, Soga K, Hirono H, et al. Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World J Gastroenterol. 2009;15:231-239.
91. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319-333.
92. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824-1832.
93. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46:1138-1145.
94. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36:150-155.
95. Trichopoulos D, Bamia C, Lagiou P, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst. 2011;103:1686-1695.
96. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533-539.
97. Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130:1639-1648.
98. Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. 2003;97:3036-3043.
99. Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol. 2005;20:1395-1400.
100. Ohfuji S, Fukushima W, Tanaka T, et al. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: a case-control study. Hepatol Res. 2006;36:201-208.
101. Montella M, Polesel J, La Vecchia C, et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer. 2007;120:1555-1559.
102. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752-1763.
103. Czaja AJ, Beaver SJ, Wood JR, Klee GG, Go VL. Frequency and significance of serum alpha-fetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1987;93:687-692.
104. Singson RC, Fraiman M, Geller SA. Hepatocellular carcinoma with fibrolamellar pattern in a patient with autoimmune cholangitis. Mt Sinai J Med. 1999;66:109-112.
105. Tapuria N, Sinha CK, Michael NG, Fisher PW. Haematogenous metastasis to ascending colon in a patient with hepatocellular carcinoma and autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2007;19:607-609.
106. Qayyum A, Graser A, Westphalen A, et al. CT of benign hypervascular liver nodules in autoimmune hepatitis. AJR. 2004;183:1573-1576.
107. Coakley FV, Schwartz LH. Imaging of hepatocellular carcinoma: a practical approach. Semin Oncol. 2001;28:460-473.
108. Sahni VA, Raghunathan G, Mearadji B, et al. Autoimmune hepatitis: CT and MR imaging features with histopathological correlation. Abdom Imaging. 2010;35:75-84.
109. Brancatelli G, Federle MP, Grazioli L, Golfieri R, Lencioni R. Large regenerative nodules in Budd-Chiari syndrome and other vascular disorders of the liver: CT and MR imaging findings with clinicopathologic correlation. AJR. 2002;178:877-883.
110. Stigliano R, Marelli L, Yu D, et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33:437-447.
111. Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57:1592-1596.
112. Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol. 2007;21:491-500.
113. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047-2063.
114. Milazzo M, Fornari F, Gramantieri L. MicroRNA and hepatocellular carcinoma: biology and prognostic significance. Minerva Gastroenterol Dietol. 2011;57:257-271.
115. Koskinas J, Petraki K, Kavantzas N, et al. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma. J Viral Hepat. 2005;12:635-641.
116. Imai H, Ochs RL, Kiyosawa K, et al. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol. 1992;140:859-870.
117. Covini G, von Muhlen CA, Pacchetti S, et al. Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol. 1997;26:1255-1265.
118. Marotta F, Vangieri B, Cecere A, Gattoni A. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ter. 2004;155:187-199.
119. Blackburn EH. Structure and function of telomeres. Nature. 1991;350:569-573.
120. Blackburn EH. Telomeres. Trends Biochem Sci. 1991;16:378-381.
121. Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-replication problem and cell aging. J Mol Biol. 1992;225:951-960.
122. Wege H, Chui MS, Le HT, Strom SC, Zern MA. In vitro expansion of human hepatocytes is restricted by telomere-dependent replicative aging. Cell Transpl. 2003;12:897-906.
123. Klapper W, Parwaresch R, Krupp G. Telomere biology in human aging and aging syndromes. Mech Ageing Dev. 2001;122:695-712.
124. Wiemann SU, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 2002;16:935-942.
125. Plentz RR, Caselitz M, Bleck JS, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology. 2004;40:80-86.
126. Plentz RR, Schlegelberger B, Flemming P, et al. Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma. Hepatology. 2005;42:522-526.
127. Plentz RR, Park YN, Lechel A, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology. 2007;45:968-976.
128. Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011;20:1238-1250.
129. Nakagomi K, Kohwi Y, Dickinson LA, Kohwi-Shigematsu T. A novel DNA-binding motif in the nuclear matrix attachment DNA-binding protein SATB1. Mol Cell Biol. 1994;14:1852-1860.
130. de Belle I, Cai S, Kohwi-Shigematsu T. The genomic sequences bound to special AT-rich sequence-binding protein 1 (SATB1) in vivo in Jurkat T cells are tightly associated with the nuclear matrix at the bases of the chromatin loops. J Cell Biol. 1998;141:335-348.
131. Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T. SATB1 targets chromatin remodelling to regulate genes over long distances. Nature. 2002;419:641-645.
132. Cai S, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet. 2003;34:42-51.
133. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008;452:187-193.
134. Selinger CI, Cooper WA, Al-Sohaily S, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011;6:1179-1189.
135. Tu W, Luo M, Wang Z, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012;32:1064-1078.
136. Tannapfel A, Busse C, Weinans L, et al. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene. 2001;20:7104-7109.
137. Jablkowski M, Bocian A, Bialkowska J, Bartkowiak J. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma. J Exp Clin Cancer Res. 2005;24:117-125.
138. Higashitsuji H, Nagao T, Nonoguchi K, et al. A novel protein overexpressed in hepatoma accelerates export of NF-kappa B from the nucleus and inhibits p53-dependent apoptosis. Cancer Cell. 2002;2:335-346.
139. Hartmann D, Srivastava U, Thaler M, et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology. 2011;53:1608-1617.
140. Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology. 2004;40:276-283.
141. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131:1758-1767.
142. Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumour cells with defined genetic elements. Nature. 1999;400:464-468.
143. Farazi PA, Glickman J, Jiang S, et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res. 2003;63:5021-5027.
144. Djojosubroto MW, Chin AC, Go N, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology. 2005;42:1127-1136.
145. Lechel A, Holstege H, Begus Y, et al. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology. 2007;132:1465-1475.
146. Tseng CS, Tang KS, Lo HW, et al. UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age. Am J Gastroenterol. 2005;100:1758-1763.
147. Lambert MP, Paliwal A, Vaissiere T, et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol. 2011;54:705-715.
148. Longerich T, Mueller MM, Breuhahn K, et al. Oncogenetic tree modeling of human hepatocarcinogenesis. Int J Cancer. 2012;130:575-583.
149. Yang YA, Zhang GM, Feigenbaum L, Zhang YE. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell. 2006;9:445-457.
150. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61-74.
151. Wong R, Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (NY). 2011;7:16-24.
152. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524.
153. Kim BK, Kim SU, Park JY, et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naive patients with hepatocellular carcinoma. Liver Int. 2012;32:1120-1127.
154. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
155. Sherman M, Bruix J, Porayko M, Tran T. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012;56:793-796.
156. Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104:1802-1829.
157. Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
158. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339-364.
159. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474.
160. Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391.
161. Hanazaki K, Kajikawa S, Shimozawa N, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000;191:381-388.
162. Yeh CN, Lee WC, Chen MF, Tsay PK. Predictors of long-term disease-free survival after resection of hepatocellular carcinoma: two decades of experience at Chang Gung Memorial Hospital. Ann Surg Oncol. 2003;10:916-921.
163. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82-89.
164. Sandhu L, Sandroussi C, Guba M, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl. 2012;18:315-322.
165. Ho CM, Lee PH, Chen CL, et al. Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria. Ann Surg Oncol. 2012;19:826-833.
166. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-1440.
167. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 1999;19:311-322.
168. Cross TJ, Antoniades CG, Muiesan P, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl. 2007;13:1382-1388.
169. Zimmermann T, Hoppe-Lotichius M, Tripkovic V, et al. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). Eur J Intern Med. 2010;21:208-215.
170. Tateishi R, Shiina S, Ohki T, et al. Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation. J Gastroenterol. 2009;44:142-146.
171. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology. 2010;78:113-124.
172. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107:569-577 (quiz 578).
173. Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther. 2011;7:463-475.
174. Izumi N. Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline. Oncology. 2010;78:78-86.
175. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 2002;3:593-603.
176. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:S115-S120.
177. Xu G, Qi FZ, Zhang JH, et al. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol. 2012;10:163.
178. Wong KM, Yeh ML, Chuang SC, et al. Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma. Indian J Gastroenterol. doi: 10.1007/s12664-012-0225-x.
179. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127:S179-S188.
180. Llovet JM, Bruix J. Systematic review of randomized trials for unrespectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442.
181. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
182. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
183. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-422.
184. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Int Med. 2012;156:387-389.
185. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101:422-434.
186. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679-690.
187. Manns MP, Czaja AJ, Gorham JD, et al. Practice guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-2213.
188. Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291-297.
189. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251-259.
190. Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204-209.
191. Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132-141.
192. Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154:85-93.
193. Milkiewicz P, Mutimer D, Hubscher SG, Elias E. Autoimmune liver disease in patients with neoplastic diseases. Eur J Gastroenterol Hepatol. 1999;11:569-573.
194. Cassani F, Zoli M, Baffoni L, et al. Prevalence and significance of abdominal lymphadenopathy in patients with chronic liver disease: an ultrasound study. J Clin Gastroenterol. 1990;12:42-46.
195. Linnell GJ, Applegate KE. Mediastinal and abdominal lymphadenopathy imitating lymphoma in an adolescent with autoimmune hepatitis. Pediatr Radiol. 2001;31:458-459.
196. Varoczy L, Gergely L, Zeher M, Szegedi G, Illes A. Malignant lymphoma-associated autoimmune diseases - a descriptive epidemiological study. Rheumatol Int. 2002;22:233-237.
197. De Block CE, De Leeuw IH, Pelckmans PA, et al. Autoimmune hepatitis, autoimmune gastritis, and gastric carcinoid in a type 1 diabetic patient: a case report. J Diabetes Complications. 2000;14:116-120.
198. Kondo H, Watanabe J, Iwasaki H. T-large granular lymphocyte leukemia accompanied by an increase of natural killer cells (CD3-) and associated with ulcerative colitis and autoimmune hepatitis. Leuk Lymphoma. 2001;41:207-212.
199. Norfleet RG, Sampson CE. Carcinoma of the cervix after treatment with prednisone and azathioprine for chronic active hepatitis. Am J Gastroenterol. 1978;70:383-384.
200. Adams B, Lazarchick J, Medina AM, et al. Iatrogenic immunodeficiency- associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol. 2010;85:627-629.
201. Lillis J, Ceilley RI, Nelson P. Merkel cell carcinoma in a patient with autoimmune hepatitis. J Drugs Dermatol. 2005;4:357-359.
202. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111:3388-3394.
203. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113-128.
204. Czaja AJ. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci. 2012;57:1996-2010.
205. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390-399.
206. Czaja AJ, Santrach PJ, Breanndan Moore S. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci. 2001;46:140-147.
207. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269-291.
208. Begley CG, Mackay IR, Bhathal PS. Another immune-mediated disease associated with hairy cell leukemia: chronic active hepatitis. Acta Haematol. 1985;73:104-105.
209. Ariad S, Song E, Cohen R, Bezwoda WR. Interferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes. Mol Biother. 1992;4:139-142.
210. Steegmann JL, Requena MJ, Garcia-Buey ML, et al. Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response. Am J Hematol. 1998;59:95-97.
211. Lebiedz P, August C, Domschke W, Schmidt HH. Interferon (IFN) for malignant melanoma unmasking an autoimmune hepatitis. Eur J Intern Med. 2009;20:e3-e4.
212. Ko KF, Ho T, Chan KW. Autoimmune chronic active hepatitis and polymyositis in a patient with myasthenia gravis and thymoma. J Neurol Neurosurg Psychiatry. 1995;59:558-559.
213. Han YS, Kim BH, Kim TH, et al. Autoimmune hepatitis in a patient with myasthenia gravis and thymoma - a report on the first case in Korea. Korean J Intern Med. 2000;15:151-155.
214. Asakawa H, Kashihara T, Fukuda H, Yamamoto M. A patient with thymoma and four different organ-specific autoimmune diseases. Neth J Med. 2002;60:292-295.
215. Aigner E, Strassburg CP, Strasser M, et al. Transient autoimmune hepatitis induced by a thymoma. Am J Gastroenterol. 2009;104:1332-1334.
216. Rodriguez-Reyna TS, Alarcon-Segovia D. Overlap syndromes in the context of shared autoimmunity. Autoimmunity. 2005;38:219-223.
217. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177-186.
218. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000;23:101-113.
219. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681-1691.
220. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268-274.
221. Strickland FM, Kripke ML. Immune response associated with nonmelanoma skin cancer. Clin Plast Surg. 1997;24:637-647.
222. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59-71.
223. Han W, Ming M, He TC, He YY. Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem. 2010;285:11369-11377.
224. Han W, Soltani K, Ming M, He YY. Deregulation of XPC and CypA by cyclosporin A: an immunosuppression-independent mechanism of skin carcinogenesis. Cancer Prev Res (Phila). 2012;5(9):1155-1162. doi: 10.1158/1940-6207.CAPR-12-0185-T
225. Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10:1385-1393.
226. Zhang YJ, Wu HC, Shen J, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res. 2007;13:2378-2384.
227. Miki D, Ochi H, Hayes CN, Aikata H, Chayama K. Hepatocellular carcinoma: towards personalized medicine. Cancer Sci. 2012;103:846-850.
228. Mizuno H, Honda M, Shirasaki T, et al. Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma. Liver Int. 2012;32:1146-1155.
229. Wan S, Hann HW, Myers RE, et al. Telomere length in circulating serum DNA as a novel non-invasive biomarker for cirrhosis: a nested case-control analysis. Liver Int. 2012;32:1233-1241.
230. Liu J, Yang Y, Zhang H, et al. Longer leukocyte telomere length predicts increased risk of hepatitis B virus-related hepatocellular carcinoma: a case-control analysis. Cancer. 2011;117:4247-4256.